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The metabolic oncogene fatty acid synthase (FASN) is overexpressed in 80% of ovarian
cancers (OC) and indicates poor prognosis. Exposure of OC to inhibitors of FASN elicits a
complex  stress  response  that  interferes  with  receptor-PI3K-mTORC1  signaling  (briefly
designated ‘PI3K pathway’). Here we demonstrate that FASN inhibitors capitalize on multiple
mechanisms to interfere with the PI3K pathway, and that silencing this cascade is crucial for
the anticancer  action of  the drugs.  Data were obtained using thin-layer chromatography,
ELISA,  Western  blotting,  quantitative  micropatterning  and  growth  assays,  respectively.
Exposure of OC cells (SKOV3, OVCAR-3) to FASN inhibitors (C75, G28UCM) causes lipid
redistribution toward storage lipids, whereas membrane lipid rafts and signaling lipids are
diminished, which significantly impairs EGF receptor/ErbB/HER function and expression. A
severe depletion of phosphatidylinositol (3,4,5) trisphosphate (PIP3), which represents the
crucial product of PI3K action, is associated with drug-dependent silencing of AKT. Moreover,
FASN  blockers  rapidly  stimulate  expression  of  the  stress  response  gene  REDD1
(RTP801/Dig2/DDIT4) followed by slow activation of the energy sensor AMPK. Induction of
these mTORC1 upstream repressors has been found to block downstream phosphorylation
of ribosomal S6 protein. Moreover, long-term stress imposed by persistent FASN blockade
leads to accelerated degradation of signaling proteins. Interestingly, concurrent targeting of
the PI3K pathway using the dual PI3K/mTOR blocker NVP-BEZ235 does not aggravate the
FASN anticancer  drug effects,  indicating that  PI3K is  already maximally  silenced due to
FASN blockade. In contrast, exogenous expression of constitutive active AKT counteracts
FASN inhibitor-mediated  mTORC1 silencing  and  abrogates  growth  arrest.  Elimination  of
PI3K downstream activity thus appears crucial for the anticancer effect of FASN blockers. On
the other hand, silencing PI3K signaling by FASN inhibitors was found to release a negative
feedback loop toward MAPK. Thus, FASN drug-mediated PI3K silencing is associated with
cross-activation  of  ERK1/2.  Accordingly, co-treatment  with  the  MEK inhibitor  selumetinib
(AZD6244)  significantly  improves  the  anticancer  action  of  FASN  inhibitors,  whereas
introduction of constitutive active MEK does not alter FASN drug-induced growth inhibition.
Collectively these data demonstrate that FASN inhibitors utilize a whole panel of different
mechanisms to abrogate receptor-PI3K-mTORC1 signaling, which represents at least one of
the crucial mechanisms of anticancer action of FASN targeting drugs. Supported by Medical
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